Table 2. . Selected studies in older patients with Ph-positive acute lymphoblastic leukemia.

Year†	Group/study	Treatment		Age	No. of patients	CR rate %	OS rate %
		Induction	Postinduction
2006	GRAALL AFR09 [76]	CTX	Imatinib + CTX	58–78	30	72	66 (1 year)
2007	GIMEMA LAL0201-B [27]	Imatinib + pred	Imatinib + PC	61–83	30	100	74 (1 year)
2007	GMALL [30]	Imatinib	Imatinib + CTX	54–79	28	96	57 (1.5 years)
		CTX	Imatinib + CTX	58–78	27	50	41 (1.5 years)
2011	GIMEMA LAL1205 [28]	Dasatinib + pred	Dasatinib + PC	24–77‡	54	100	69 (1.5 years)
2015	MD Anderson [22]	Dasatinib + CTX	Dasatinib + CTX	21–80§	72	96	46 (5 years)
2015	MD Anderson [33,34]	Ponatinib + CTX	Ponatinib + CTX	21–80	64	98	76 (3 years)
2016	EWALL-PH-01 [32]	Dasatinib + CTX	Dasatinib + CTX	59–83	71	96	36 (5 years)

^†Year of study publication.

^‡12 patients >60 years.

^§46 patients >50 years.

ALL: Acute lymphoblastic leukemia; CR: Complete response; CTX: Chemotherapy; OS: Overall survival; PC: Physician choice; Pred: Prednisone.